The global low-grade Glioma therapeutics market is expected to garner a market value of USD 1038 Million in 2023 and is expected to accumulate a market value of USD 1515.47 Million by registering a CAGR of 4.57% in the forecast period 2023-2033. Growth of the low-grade Glioma therapeutics market can be attributed to increasing prevalence of low-grade glioma and research and development to innovate medications.
The market for low-grade Glioma therapeutics registered a CAGR of 3.4% in the historical period 2018 to 2022
Low-grade gliomas are a type of brain tumor that grow slowly and are often classified as Grade I or Grade II on the World Health Organization (WHO) grading scale. These types of tumors can be difficult to treat because they often infiltrate surrounding brain tissue and can be difficult to completely remove surgically.
Low-grade glioma therapeutics refers to the treatments used to manage low-grade gliomas, a type of slow-growing brain tumor. The goal of these treatments is to remove as much of the tumor as possible, prevent recurrence, and preserve normal brain function. The main therapeutic options include surgery, radiation therapy, and chemotherapy. The choice of treatment is personalized and depends on various factors such as the location and size of the tumor and the patient's overall health.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1038 Million |
| Anticipated Forecast Value (2033) | USD 1515.47 Million |
| Projected Growth Rate (2023 to 2033) | 4.57% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
According to market research and competitive intelligence provider Future Market Insights- the market for Low-grade Glioma therapeutics reflected a value of 3.4% during the historical period, 2018 to 2022.
Increased research and development activities in the field of low-grade glioma therapeutics have resulted in the development of new and improved treatments, further driving growth in the market. Moreover, increasing healthcare expenditure, driven by factors such as an aging population and increasing awareness of the need for effective treatments for low-grade gliomas, has also contributed to the growth of the market.
Thus, the market for Low-grade Glioma therapeutics is expected to register a CAGR of 4.57% in the forecast period 2023 to 2033.
New and effective medical technologies spurring growth of low-grade Glioma therapeutics
The incidence of brain tumors, including low-grade gliomas, is increasing globally, driving demand for effective treatments. There has been an increase in public and medical awareness of low-grade gliomas, which is leading to earlier diagnoses and more effective treatments. The development of new and more effective medical technologies for the diagnosis and treatment of low-grade gliomas is driving the growth of the market.
Increased healthcare expenditure globally, especially in developed countries, is driving the growth of the low-grade glioma therapeutics market as people are more willing to pay for effective treatments. The increasing focus on research and development of new treatments for low-grade gliomas is leading to the development of new and more effective therapies, driving market growth.
Availability of different treatments driving growth of Glimoa therapeutics
Surgery: The goal of surgical treatment is to remove as much of the tumor as possible while preserving normal brain function. In some cases, the entire tumor may be removed, but in many cases, only a portion can be safely removed.
Radiation therapy: Radiation therapy uses high-energy beams to destroy the tumor cells. This treatment is often used after surgery to help kill any remaining tumor cells and reduce the risk of recurrence.
Chemotherapy: Chemotherapy involves the use of drugs to kill cancer cells. It is not commonly used to treat low-grade gliomas as these tumors are often resistant to chemotherapy.
Targeted therapy: Targeted therapy uses drugs to specifically target the cancer cells, rather than damaging normal cells. This type of therapy is still being studied for the treatment of low-grade gliomas, but it has shown promise in early clinical trials.
Difficulty in diagnosing and expensive treatments creating obstacles for low-grade therapeutics market
The cost of treatments for low-grade gliomas is high, making them inaccessible to many patients, especially in developing countries. Currently, there are limited effective treatments for low-grade gliomas, and many of the available treatments come with significant side effects.
Low-grade gliomas can be difficult to diagnose, and the symptoms are often similar to those of other neurological conditions, making it difficult for physicians to make an accurate diagnosis. The underlying causes of low-grade gliomas are not well understood, making it difficult to develop new and effective treatments.
The low-grade glioma therapeutics market faces competition from alternative treatments, such as radiation therapy and chemotherapy, which are less invasive and less expensive.
Research and development leading to innovation of medications for treating low-grade glioma therapeutics in North America
The North America low-grade glioma therapeutics market is one of the largest and most mature markets in the world. The market is driven by factors such as a high incidence of brain tumors, an aging population, increasing awareness of low-grade gliomas, and rising healthcare expenditure.
In North America, the United States is the largest market for low-grade glioma therapeutics, driven by factors such as a high incidence of brain tumors, a large and aging population, and a high level of healthcare expenditure. Canada is also a significant market for low-grade glioma therapeutics, driven by factors such as an aging population and increasing healthcare expenditure.
The North America low-grade glioma therapeutics market is dominated by major players such as Roche, Novartis, and Pfizer, who offer a range of treatments for low-grade gliomas, including chemotherapy, radiation therapy, and surgical treatments. The market is expected to continue to grow in the coming years, driven by advances in medical technology and increasing research and development activities in the field.
Overall, the North America low-grade glioma therapeutics market offers a significant opportunity for growth, driven by a large and aging population, increasing awareness of low-grade gliomas, and rising healthcare expenditure. Thus, North America is expected to possess 45% market share for low-grade glioma therapeutics market in 2023.
Rising healthcare expenditure bolstering the market for low-grade glioma therapeutics
The Europe low-grade glioma therapeutics market offers a significant opportunity for growth, driven by a large and aging population, increasing awareness of low-grade gliomas, and rising healthcare expenditure. In Europe, the market is driven by a number of countries, including the United Kingdom, Germany, France, Italy, and Spain, which are among the largest markets for low-grade glioma therapeutics in the region.
The Europe low-grade glioma therapeutics market is dominated by major players such as Roche, Novartis, and Pfizer, who offer a range of treatments for low-grade gliomas, including chemotherapy, radiation therapy, and surgical treatments.
The market is expected to grow at a moderate pace in the coming years, driven by advances in medical technology and increasing research and development activities in the field. Thus, Europe is expected to possess 37% market share for low-grade glioma therapeutics market in 2023.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Access to wider drugs making hospital pharmacies popular for low-grade glioma therapeutics
Hospital pharmacists have specialized training in managing and dispensing medications for patients with neurological conditions, including low-grade gliomas. This expertise can help ensure that patients receive the most appropriate and effective treatments for their condition. In addition, hospital pharmacies play a key role in coordinating care for patients with low-grade gliomas. Pharmacists can work with other healthcare providers, such as neurologists and oncologists, to ensure that patients receive the most appropriate and effective treatments for their condition.
Hospital pharmacies have access to a wider range of specialty drugs, including those used to treat low-grade gliomas. This can be especially important for patients with rare or complex conditions, who may require treatments that are not widely available.
Hospital pharmacists can monitor patients' treatments for low-grade gliomas, including monitoring for potential side effects and drug interactions. This can help ensure that patients receive the most effective and safe treatments for their condition. Thus, hospital pharmacies are expected to procure 40% market share for low-grade glioma therapeutics market in 2023.
Key players in the low-grade Glioma therapeutics market are Day One Biopharmaceuticals, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Servier, Helsinn, Forma Therapeutics, Hoffmann-La Roche, Incyte, Eli Lilly
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1038 Million |
| Market Value in 2033 | USD 1515.47 Million |
| Growth Rate | CAGR of 4.57% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Class, Route of Administration, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa(MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Austria, New Zealand, GCC countries, South Africa, Israel, Rest of Middle East and Africa(MEA) |
| Key Companies Profiled | Day One Biopharmaceuticals; AnHeart Therapeutics; Beigene; SpringWorks Therapeutics; Servier; Helsinn; Forma Therapeutics; Hoffmann-La Roche; Incyte; Eli Lilly |
| Customization | Available Upon Request |
The total market is estimated to accumulate USD 1,038 million revenue in 2023.
The global market is forecasted to grow at 4.57% CAGR through 2033.
The overall global market could reach a value of USD 1,515.47 million by 2033.
North America market could contribute significantly with a 45% share in 2023.
AnHeart, Beigene, and Springworks are some popular companies in the global market.
| Estimated Market Size (2024E) | USD 37.5 billion |
|---|---|
| Projected Market Value (2034F) | USD 112.8 billion |
| Value-based CAGR (2024 to 2034) | 11.7% |
| Market Value for 2023 | USD 15,246.7 million |
|---|---|
| Projected Market Value for 2033 | USD 30,318.5 million |
| Value-based CAGR of Market for 2023 to 2033 | 7.1% |
| Expected Market Value (2023) | USD 147.9 Million |
|---|---|
| Projected Forecast Value (2033) | USD 412.4 Million |
| CAGR (2023 to 2033) | 10.8% |
| Expected Market Value (2023) | USD 1.2 Billion |
|---|---|
| Anticipated Forecast Value (2033) | USD 3.72 Billion |
| Projected CAGR (2023 to 2033) | 12% |
Explore Therapy Area Insights
View Reports
Low-Grade Glioma Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
